Core Viewpoint - The company, AVIC Chengfei (302132), expects a net profit attributable to shareholders of 3.4 billion to 3.6 billion yuan for 2025, representing a year-on-year increase of 5.47% to 11.67% after restructuring [1] Group 1: Financial Performance - The company completed a significant asset restructuring project, which has enhanced its profitability [1] - The projected net profit range for 2025 indicates a strong financial outlook and growth potential [1] Group 2: Business Focus - The company has added new business lines in the development and production of complete aircraft and related components, focusing on its core aviation business [1] - This strategic focus is expected to further strengthen the company's risk resistance and core competitiveness [1]

人民财讯1月26日电，广期所1月26日发布市场风险提示函称，近期，受多重因素影响，广期所部分品种 价格波动较大。请各会员单位切实履行风险管理职责，强化客户交易行为合规监管和风险防范，提醒投 资者依规、谨慎、理性参与交易，确保市场平稳运行。交易所将坚持严监严管主基调，持续强化市场监 管，严肃查处各类违规行为，加强实际控制关系账户调查、认定，发挥五位一体监管协作合力，依法严 厉打击市场操纵行为，维护市场秩序。 ...

人民财讯1月26日电，浙海德曼(688577)1月26日公告，公司拟向特定对象发行股票，募资总额不超过 15.17亿元，用于高端复合化机床产业化项目、高端精密机床与机器人硬件智造研发项目及补充流动资 金。 ...

Core Viewpoint - Huatai-PB announced the renaming of its "Dividend Family Bucket" series, which currently has a scale exceeding 52 billion yuan, to include the management name "Huatai-PB" starting from January 28 [1] Group 1 - The new abbreviations for the related products will be: Dividend ETF Huatai-PB, Low Volatility Dividend ETF Huatai-PB, Hong Kong Stock Connect Dividend ETF Huatai-PB, Central State-Owned Enterprise Dividend ETF Huatai-PB, and Hong Kong Stock Connect Low Volatility Dividend ETF Huatai-PB [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has suspended the import, sale, and use of the cabozantinib capsules produced by Sun Pharmaceutical Industries Limited due to quality management deficiencies and non-compliance with production standards [1] Group 1: Regulatory Actions - NMPA conducted a remote inspection of Sun Pharmaceutical Industries Limited regarding the cabozantinib capsules [1] - The inspection revealed that the company's quality management department lacked sufficient capability, leading to inadequate risk assessment for certain batches of marketed products [1] - As a result, NMPA has decided to halt the importation, sale, and usage of the cabozantinib capsules immediately [1] Group 2: Compliance Issues - The inspection found defects in the production process related to contamination prevention and adherence to the Chinese Pharmacopoeia [1] - Sun Pharmaceutical Industries Limited's practices were deemed non-compliant with the Drug Production Quality Management Standards (2010 revision) of China [1] - The drug supervision departments at various import ports have been instructed to suspend the issuance of import clearance documents for the affected product [1]

进入2026年，深圳二手房市场的成交表现引起市场关注。 1月26日，深圳市房地产中介协会发布的数据显示，上周全市二手房(含自助)共计录得1680套，环比增 长1.6%。进入2026年，市场进入稳步回升通道，二手房录得量已连续3周保持上升趋势且单周录得量再 次突破1600套。与此同时，从需求端(委买合同)来看，市场新增需求量小幅上升，结合二手录得量持续 走高，表明当前市场供需两端均呈现回暖态势，后续成交量有望延续稳中有升的走势。 二手房一直被视为市场的"晴雨表"。中指研究院认为，随着住房市场进入存量时代，二手房成交占比逐 步提升，在大中城市，刚需购房者普遍通过购买二手房解决居住问题，而新房市场则转向满足改善性需 求，房企通过"好房子"产品形成差异化供给。根据中指数据，2025年30城二手房成交套数同比基本持 平，二手房占比提升至65%左右，较2024年提升约4个百分点。北京、上海、广州、深圳、成都、杭 州、南京、苏州等核心城市二手房成交套数占比均超六成。 中指研究院认为，由于2026年春节假期相对延后，传统销售淡季窗口相应后移，使得1月至2月上旬市场 表现成为观测一季度乃至全年景气度的关键窗口。短期市场能否实现 ...

人民财讯1月26日电，中农联合（003042）1月26日发布2025年度业绩预告，公司预计2025年度归属于上 市公司股东的净利润亏损1.28亿元—1.65亿元，上年同期亏损1.22亿元。报告期内，受公司主要产品市 场价格持续低位下行影响，公司主营业务毛利率偏低，同时，新建成项目试运行期间成本较高，导致公 司报告期内业绩亏损额有所增加。 ...

签约仪式于理大校园举行，爱博医疗创始人、董事长兼总经理解江冰博士和理大高级副校长（研究及创 新）赵汝恒教授代表双方签署合作协议。 1月26日，爱博医疗(688050)与香港理工大学（以下简称"理大"）签署合作协议，双方将在合作研发、 临床转化与人才培育三大核心维度深度联动，构建长效稳固的战略协同机制。 双方亦将通过技术验证与应用试点，借助爱博医疗商业化能力与市场化运营能力，加速科研成果落地， 实现创新技术与产业需求的有效衔接。爱博医疗设有眼科视光奖学金，可提供科研实践、实习岗位，理 大具有人才培养、国际视野、全球资源等优势，双方共建联合培养机制，可实现人才成长与产业发展的 精准匹配。同时，爱博医疗还将和理大初创企业瞳研科技有限公司共同探索近视控制前沿科技，助力大 学科研成果产业化落地。 爱博医疗始终秉持开放协作的理念。公司长期与国内眼科医院、行业协会紧密合作，共建教学实践基 地，持续为行业输送高素质专业人才，同时深度参与行业标准的制定与完善。此次签约将成为公司发展 新起点，助力中国眼科技术走向国际舞台。 解江冰博士表示："爱博医疗始终将创新视为发展的驱动力。理大在眼科视光领域处于国际领先地位， 是全球该领域重 ...

Core Viewpoint - Zhongke Electric (300035) forecasts a net profit attributable to shareholders of 455 million to 515 million yuan for the year 2025, representing a year-on-year growth of 50% to 70% [1] Group 1: Financial Performance - The company expects a significant increase in net profit for 2025, with projections between 455 million and 515 million yuan [1] - This anticipated growth reflects a strong performance compared to the previous year, indicating a robust financial outlook [1] Group 2: Production and Market Demand - The production capacity of lithium battery anode materials has increased compared to the previous year [1] - There is a growing demand in the downstream market, particularly for new energy vehicles, especially fast-charging models, and the energy storage market [1] - The sales volume of lithium-ion battery anode materials has seen substantial growth compared to the same period last year [1]

人民财讯1月26日电，恒基达鑫（002492）1月26日发布2025年度业绩预告，预计2025年归属于上市公司 股东的净利润亏损5800万元至7500万元，上年同期实现净利润6510.78万元。2025年度，归属于上市公 司股东的净利润较上年同期出现变动，主要原因系公司严格遵循《企业会计准则》及自身会计政策，基 于谨慎性原则，对报告期内各类资产全面开展核查与减值测试，并据此计提各项资产减值准备及信用减 值损失，该事项不影响公司主营业务的持续经营能力。 ...